Pricing Log in Create free account
Friday 6 November 2026 Export CLLS’s income statement to Excel — free account

Cellectis S.A.

CLLS Healthcare Biotechnology

Cellectis S.A.’s revenue for fiscal 2025 (year ended December 2025) was $79.6 million, up 61.7% from fiscal 2024.

Revenue
−62.1%
EPS
+8.33%
Free cash flow
−37.0%
Total debt
−0.54%

Quarter to June 2026, against a year earlier

1.07 0.04 +3.88%
Market cap
$74.5M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
2/9
Altman Z
−0.03
Beneish M
−2.61
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 30.97%

Capital & Financial Ratios $m

Size
Market Cap 74.50
Revenue ttm 63.82
Net income ttm (65.31)
Free cash flow ttm (43.80)
Net debt Q (93.16)
Valuation
P/E 0.00
Forward P/E —
Price / sales 1.69
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.62
Financial health
Current ratio Q 1.37
Debt / equity Q 1.79
Interest coverage Q (7.81)
Growth
Revenue growth Q −62.05% (below 0%: shrinking)
Operating income growth Q −145.34% (below 0%: shrinking)
EPS, this year −19.90% (below 0%: weak)
EPS, next year A +17.01% (at or above 15%: strong)
Revenue, next year A —
EPS, past 5 yrs —
EPS, next 5 yrs A −26.03% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.2×, against a ten-year median of 5.6×; over the ten years it ranged from −3.3× in 2022 to 26.9× in 2019.
P/S against its own 10 years 0.41%
10-year low 10-year high
P/B against its own 10 years 64.85%
10-year low 10-year high
EV/Sales against its own 10 years 1.71%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 204 260 209 167
Receivables 21 21 22 13
Inventory — — — —
Other 8 6 5 5
233 287 236 184
2023 2024 2025 Q'26
Payables 19 19 17 18
ST’ Debt 5 16 10 8
Other 12 11 14 12
155 166 146 135

Compound Annual Growth %

10y 5y 3y
Sales 3.60% (0.70%) 45.72%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (12.63%) (24.47%) (15.53%)

Earnings Trends EPS, adjusted, against the consensus

Dec 2024 Estimate 0.06 Actual −0.16

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Sep 2023 −0.36 −0.31 Beat by 0.05
Jun 2024 −0.33 −0.28 Beat by 0.05
Sep 2024 −0.20 −0.23 Miss by 0.03
Dec 2024 0.06 −0.16 Miss by 0.22

EPS $

Mar Jun Sep Dec Year
’26 (0.18) (0.22) — — —
’25 (0.18) (0.24) 0.01 (0.26) (0.67)
’24 0.05 (0.28) (0.23) 0.05 (0.41)
’23 (0.58) (0.19) (0.31) (0.64) (1.77)
’22 (0.70) (0.42) (0.63) (0.59) (2.33)
’21 (0.28) (0.88) (0.82) (0.55) (2.55)
’20 0.47 (0.76) (0.71) (0.95) (1.91)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 8 7 — — —
’25 12 18 37 12 80
’24 6 10 18 15 49
’23 4 2 2 2 9
’22 4 3 2 17 26
’21 28 15 11 (15) 39
’20 52 5 9 17 82
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (15) (14) — — —
’25 (17) (10) (2) (10) (39)
’24 (23) 52 (6) 0 23
’23 (28) (19) (17) 40 (25)
’22 (37) (24) (26) (1) (87)
’21 (41) (12) (30) (21) (105)
’20 1 (22) (26) (34) (80)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) (15) — — —
’25 (18) (11) (4) (11) (43)
’24 (24) 51 (7) (2) 19
’23 (29) (21) (17) 39 (26)
’22 (37) (25) (27) (1) (90)
’21 (49) (18) (36) (21) (123)
’20 (6) (36) (32) (52) (126)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 56 34 21 23 82 39 26 9 49 80 64 +3.9% — — — —
Gross margin, % 96.85 92.23 87.22 50.45 56.01 95.22 93.11 91.98 100.00 100.00 100.00 +3.1 pt
EBT (67) (104) (88) (115) (97) (97) (99) (116) (37) (68) (66) +0.1%
EBT margin, % (119.15) (307.53) (412.15) (501.14) (118.22) (250.66) (383.29) (1,266.89) (74.69) (85.46) (102.89) +33.7 pt
Net income (67) (104) (88) (115) (97) (97) (99) (117) (37) (68) (65) +0.1%
Per share, $
Per share, $ Revenue 1.60 0.94 0.53 0.54 1.94 0.86 0.56 0.16 0.54 0.79 0.63 (7.5%)
Earnings (1.90) (2.78) (1.93) (2.41) (1.91) (2.55) (2.33) (1.77) (0.41) (0.67) (0.65) (10.9%)
Cash flow (0.93) (1.47) (1.67) (1.63) (1.89) (2.33) (1.92) (0.43) 0.25 (0.39) (0.41) (9.1%)
Capex (0.40) 0.13 (0.09) (0.30) (1.09) (0.41) (0.05) (0.02) (0.04) (0.04) (0.02) (23.6%)
Free cash flow (1.32) (1.34) (1.76) (1.92) (2.98) (2.75) (1.97) (0.45) 0.21 (0.43) (0.44) (11.8%)
Book value 7.79 7.96 11.04 8.38 7.27 5.28 2.77 1.49 1.45 0.76 0.41 (22.8%)
Shares, m 35 36 41 42 43 45 46 57 91 100 100 +12.3%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 11.32 31.85 31.68 31.61 13.95 9.43 4.02 19.04 3.66 6.10 1.69 16.3
P/B 2.33 3.78 1.51 2.04 3.72 1.54 0.82 2.07 1.38 6.39 2.62 2.6
EV/Sales 6.20 23.05 10.65 17.98 11.13 5.19 1.22 2.79 (0.26) 4.54 0.23 8.2
EV/FCF (7.49) (16.25) (3.18) (5.06) (7.25) (1.63) (0.35) (0.93) (0.68) (8.18) (0.31) (5.1)
Cash, $m
Cash, $m Operating cash flow (33) (52) (68) (69) (80) (105) (87) (25) 23 (39) (42) +2.1%
Capex (14) 5 (4) (13) (46) (19) (2) (1) (4) (4) (2) (14.2%)
Free cash flow (47) (48) (72) (82) (126) (123) (90) (26) 19 (43) (44) (0.9%)
Balance, $m
Balance, $m Working capital 256 278 441 329 263 176 81 78 121 90 49 (10.9%)
Net debt (289) (297) (451) (313) (233) (164) (72) (149) (193) (124) (93) (9.0%)
Shareholders’ equity 275 284 450 355 309 236 126 85 131 76 41 (13.3%)
Returns, %
Returns, % ROA (18.94) (29.92) (18.88) (21.09) (17.31) (26.82) (33.00) (33.94) (10.24) (19.09) (21.02) (0.1) pt
ROIC 0.00 0.00 0.00 (182.91) (70.08) (88.93) (104.04) 0.00 0.00 0.00 0.00 0.0 pt
ROE (23.71) (35.57) (21.43) (25.34) (24.41) (41.88) (58.57) (95.96) (34.08) (65.33) (94.54) (41.6) pt
People
People Employees 122 135 171 264 281 294 237 221 222 229 — +7.2%
Revenue/emp, $m 0.46 0.25 0.13 0.09 0.29 0.13 0.11 0.04 0.22 0.35 — (3.1%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Cellectis S.A. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ATRA Atara Biotherapeutics, Inc. $79.9M — (loss-making) — (loss-making) −96.42% (below 0%: shrinking) n/m +52.10% (above 0%: growing) 69.68% (749.21%) Compare
TLSA Tiziana Life Sciences Ltd $79.6M — (loss-making) — — −258.11% (below 0%: shrinking) +18.03% (above 0%: growing) 0.00% — Compare
TNXP Tonix Pharmaceuticals Holding Corp. $78.9M — (loss-making) — (loss-making) +577.88% (above 0%: growing) n/m −178.84% (below 0%: shrinking) 94.81% (314.05%) Compare
NRXS Neuraxis, Inc. $76.7M — (loss-making) — (loss-making) +115.71% (above 0%: growing) n/m +29.76% (above 0%: growing) 85.87% (110.16%) Compare
CLLS Cellectis S.A. $74.5M — (loss-making) — −62.05% (below 0%: shrinking) n/m −36.95% (below 0%: shrinking) 100.00% (340.69%)
OKYO OKYO Pharma Limited Sponsored ADR $73.5M — (loss-making) — — n/m +37.39% (above 0%: growing) 0.00% — Compare
TNYA Tenaya Therapeutics, Inc. $72.0M — (loss-making) — — n/m −13.18% (below 0%: shrinking) 100.00% (1,153.33%) Compare
RANI Rani Therapeutics Holdings, Inc. $72.0M — (loss-making) — (loss-making) 0.00% n/m −55.29% (below 0%: shrinking) 100.00% (516.86%) Compare
MNOV MediciNova, Inc. $71.4M — (loss-making) — (loss-making) +240.56% (above 0%: growing) n/m +16.75% (above 0%: growing) 69.33% (554.36%) Compare
Median of peers $75.1M — — +115.71% — +17.39% 77.77% (535.61%)

All 621 Biotechnology stocks →

Cellectis S.A. (CLLS) Latest News

27 Oct

Impact 4 · · GlobeNewswire

1 Oct

Impact 4 · · MarketBeat

17 Sep

Impact 4 ·

15 Sep

Impact 4 · · Stocktwits

14 Sep

Impact 4 · · InvestorsHub
Impact 4 · · biopharmadive.com
Impact 4 ·

11 Jun

Impact 4 ·
Impact 3 · · GlobeNewswire

9 Jun

Impact 4 · · Stocktwits
Impact 4 · · GlobeNewswire

12 May

Impact 4 · · GlobeNewswire

11 May

Impact 4 · · GlobeNewswire

27 Apr

Impact 4 · · GlobeNewswire

13 Apr

Impact 4 · · GlobeNewswire

20 Mar

Impact 4 · · GuruFocus.com

19 Mar

Impact 4 · · GlobeNewswire

23 Jan

Impact 3 · · Simply Wall St.

8 Jan

Impact 4 · · GlobeNewswire

15 Dec

Impact 4 · · GlobeNewswire
Impact 3 · · GlobeNewswire

11 Dec

Impact 3 · · Simply Wall St.

8 Dec

Impact 4 ·

25 Nov

Impact 3 · · MT Newswires

21 Nov

Impact 4 · · PR Newswire

19 Nov

Impact 4 · · GlobeNewswire

7 Nov

Impact 3 · · GlobeNewswire

3 Nov

Impact 4 ·

16 Oct

Impact 4 · · GlobeNewswireClinical Trials ArenaMT NewswiresClinical Trials ArenaMT NewswiresPharmaceutical TechnologyTipRanksSimply Wall St.
Impact 4 · · GlobeNewswire
stockrow.com/CLLS · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com